Infliximab eye drops after first corneal transplant
Part of Eyes & vision clinical trials.
This trial tests infliximab—given as eye drops—after a first corneal transplant to see if it can improve healing and eye outcomes. It may help people at risk of inflammation after surgery, but it also requires careful screening for infection and medication safety.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 80 years old
- This is your first corneal transplant surgery
- You (or a caregiver) can give the eye drops and follow study instructions
- You have no active infection in or around the eye
- You do not have certain serious conditions like advanced glaucoma, major macular disease, or past corneal transplants
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether an eye drop version of infliximab, a medication that reduces inflammation, can help people with Sjögren's syndrome who have severe dry eye. You would keep taking your current medications and add these drops to see if they improve symptoms and eye surface damage.
This study tests whether anti-inflammatory eye drops (nepafenac, an NSAID) can help reduce swelling in the macula (the sharp-vision part of the eye) after certain cornea transplant surgeries. It compares outcomes in adults having DSAEK or DMEK who can safely use the study drops.
This trial compares two ways to manage inflammation after corneal crosslinking for keratoconus: a tiny steroid insert placed in the tear duct versus standard steroid eye drops. It aims to see which option is easier and works just as well.
This trial tests whether injecting Humira (adalimumab) under the membrane of the eye can improve outcomes for people receiving a special type of artificial cornea called a Boston keratoprosthesis. It is for patients with severe corneal scarring and poor vision.
This trial looks at how often inflammatory flare-ups happen in patients with a type of eye inflammation called posterior uveitis. It focuses on people who have been treated with a fluocinolone acetonide implant, a tiny device placed in the eye that releases medicine over time, and aims to understand how well it controls inflammation.
This trial tests a new eye drop (tacrolimus) to treat non-infectious anterior uveitis, an inflammation in the front part of the eye. It may help reduce the need for steroid eye drops.
Hear when a new Glaucoma Following Surgery trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.